CD19 and B-cell acute lymphoblastic leukemia: CD19-targeted chimeric antigen receptor T cells (CD19-CAR) and blinatumomab have shown efficacy in inducing remission among relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) patients.